Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.57 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CD38 | P28907 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.48 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576032 | 0.87 | EPHX2 (0.55) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL16709610 | 0.85 | EPHX2 (0.44) | EPHX2MAOBALOX5CYP3A4CD38 | |
| SCHEMBL3232626 | 0.84 | EPHX2 (0.62) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL16709599 | 0.84 | P2RX7 (0.55) | P2RX7 | |
| SCHEMBL16709640 | 0.84 | P2RX7 (0.56) | EPHX2CYP3A4CD38P2RX7CNR1 | |
| SCHEMBL38654586 | 0.83 | EPHX2 (0.57) | EPHX2PPARGP2RX7CNR1CNR2 | |
| SCHEMBL16215806 | 0.83 | EPHX2 (0.57) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL3233426 | 0.83 | EPHX2 (0.57) | EPHX2PPARGP2RX7CNR1CNR2 | |
| SCHEMBL16108275 | 0.83 | EPHX2 (0.50) | EPHX2PPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL10310453 | 0.83 | EPHX2 (0.50) | EPHX2PPARGHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2019306-A | — | — | None | — | — | JP | disclosed |
| WO-2014078331-A1 | N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-22 | — | — | US | disclosed |
| CN-101090723-A | Piperazine urea derivatives for the treatment of endometriosis | SCHERING AG (DE) | 2007-12-19 | — | — | CN | disclosed |
| US-7268140-B2 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AG (DE) | 2007-09-11 | — | — | US | disclosed |
| CN-1938029-A | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | UNIV PITTSBURGH (DE) | 2007-03-28 | — | — | CN | disclosed |
| EP-1713483-A1 | CHEMOKINE INHIBITING PIPERAZINE DERIVATIVES AND THEIR USE TO TREAT MULTIPLE MYELOMA | Schering Aktiengesellschaft (DE) | 2006-10-25 | — | — | EP | disclosed |
| CN-1838957-A | Chemokine inhibiting piperazine derivatives and their use to treat myocarditis | SCHERING AKTIEGESELLSCHAFT (DE) | 2006-09-27 | — | — | CN | disclosed |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | BAUMAN JOHN G | 2006-06-22 | — | — | US | disclosed |
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| US-6573266-B1 | Compounds used for treating multitiple sclerosis and encephalomyelitis | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-6555537-B2 | Inhibit activity of chemokines, macrophage inflammatory protein-1 (MIP-1 alpha) and RANTES; 1-((4-chlorophenoxy)methyl)-carbonyl-2-methyl-4-(4-fluorobenzyl)piperazine for example | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| US-6541476-B1 | Treating multiple sclerosis or encephalomyelitis in a human | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-01 | — | — | US | disclosed |
| US-6534509-B1 | Derivatives are useful as anti-inflammatory agents. This invention is also directed to pharmacetutical compostions for inflammation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-18 | — | — | US | disclosed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | SCHERING AKTIENGSCHELLSCHAFT | 2002-11-28 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| JP-H0219306-A | AGRICULTURAL AND HORTICULTURAL GERMICIDE | AGRO KANESHO CO LTD | 1990-01-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139425-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | EPHX2 618/4885PPARG 161/4885HDAC3 97/4885 |
| US-20060135487-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | EPHX2 618/4885PPARG 161/4885HDAC3 97/4885 |
| US-20080269247-A1 | Chemokine Inhibiting Piperazine Derivatives and Their Use to Treat Myocarditis | CCL2, CCR2, CXCL10 | EPHX2 1391/4885PPARG 773/4885HDAC3 387/4885 |
| US-20020177598-A1 | Piperazine derivatives and their use as anti-inflammatory agents | IL5, PTGES2, PTGES | EPHX2 618/4885PPARG 161/4885HDAC3 97/4885 |
| US-20080119471-A1 | Piperazine urea derivatives for the treatment of endometriosis | ESR2, GPER1, SLC14A1 | EPHX2 2184/4885PPARG 385/4885HDAC3 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.